Welcome to our dedicated page for Royalty Pharma plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
The board of directors of Royalty Pharma (RPRX) has approved a fourth-quarter 2021 dividend of $0.17 per Class A ordinary share. This dividend will be paid on December 15, 2021, to shareholders of record as of November 19, 2021. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation through partnerships with various biotechnology and pharmaceutical companies. Their portfolio includes royalties from over 45 commercial products, enhancing their financial stability and attractiveness to investors.
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in September 2021. The events include Citi’s 16th Annual BioPharma Virtual Conference on September 9 at 10:40 a.m. EDT and Morgan Stanley’s 19th Annual Global Healthcare Conference on September 14 at 11:00 a.m. EDT. Webcasts will be available on Royalty Pharma’s 'Events' page and archived for at least 30 days. Royalty Pharma is known for acquiring biopharmaceutical royalties and funding innovation in the industry, with royalties on over 45 commercial products.
Royalty Pharma reported a strong second quarter for 2021, achieving a 9% increase in net cash provided by operating activities to $532 million, and a 3% rise in Adjusted Cash Receipts to $475 million. The company has raised its full-year 2021 guidance for Adjusted Cash Receipts to between $2,080 and $2,120 million, reflecting solid revenue growth driven by its cystic fibrosis franchise and new royalty acquisitions. Notably, Royalty Pharma completed up to $2.8 billion in announced transactions in 2021, solidifying its position in the biopharma royalty market.
Royalty Pharma plc (RPRX) is set to report its second quarter financial results on August 11, 2021, prior to the U.S. market opening. The company will conduct a conference call at 8:00 a.m. Eastern Time, accessible via phone and a live webcast on their website. Royalty Pharma is recognized as the largest buyer of biopharmaceutical royalties, collaborating with various institutions and companies to fund innovation in the biopharmaceutical sector. The firm holds royalties on over 45 commercial products, aiding in therapy development and commercialization.
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a third-quarter dividend of $0.17 per Class A ordinary share. This dividend will be paid on September 15, 2021, to shareholders on record by the close of business on August 20, 2021. Royalty Pharma is a leading buyer of biopharmaceutical royalties and funds innovation across the biopharmaceutical industry, holding royalties for over 45 commercial products, including well-known therapies like Imbruvica and Xtandi.
Royalty Pharma (Nasdaq: RPRX) has successfully priced an offering of $1.3 billion in senior unsecured notes. This includes $600 million of 2.15% Senior Notes due in 2031 and $700 million of 3.35% Senior Notes due in 2051. The proceeds from the Social Bonds will support investments aligned with United Nations Sustainable Development Goals, while the 2051 Notes will finance general corporate purposes. The offering is set to close on July 26, 2021, pending customary conditions.
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in June 2021. The first event is the Goldman Sachs Global Healthcare Conference on June 9 at 3:50 p.m. EDT, followed by the Bank of America Napa Biopharma Conference on June 15 at 1:30 p.m. EDT. Interested parties can access webcasts from Royalty Pharma’s “Events” page, with recordings available for at least 30 days. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.
Royalty Pharma has announced a $2.025 billion strategic funding partnership with MorphoSys to facilitate its $1.7 billion acquisition of Constellation Pharmaceuticals. This agreement includes an upfront payment of $1.425 billion, milestone payments of up to $150 million, and up to $350 million in Development Funding Bonds. Royalty Pharma will acquire future royalties from the blockbuster drug Tremfya, with 2020 sales reaching $1.347 billion, and rights to royalties from four development-stage therapies. The deal aims to enhance Royalty Pharma's portfolio and supports MorphoSys’s growth strategy.
Royalty Pharma (RPRX) reported strong Q1 2021 results, with GAAP net cash from operations rising 12% to $526 million and total revenues up 14% to $573 million. Adjusted Cash Receipts surged 37% to $524 million, driven by growth in its cystic fibrosis and oncology portfolios. The company announced new royalty transactions totaling $787 million, including $582 million in upfront payments. Royalty Pharma raised its 2021 Adjusted Cash Receipts guidance to $1,940-$1,980 million, reflecting positive business momentum and portfolio expansion.
Royalty Pharma plc (Nasdaq: RPRX) will participate in three investor conferences in May 2021: the Bank of America 2021 Healthcare Conference on May 12, the Truist Securities Life Sciences Summit on May 20, and the UBS Global Healthcare Virtual Conference on May 24. All events will be accessible via the company’s Events page, and webcasts will be archived for at least thirty days.
Royalty Pharma is a leading buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.
FAQ
What is the current stock price of Royalty Pharma plc (RPRX)?
What is the market cap of Royalty Pharma plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
